tradingkey.logo
tradingkey.logo
Search

iSpecimen Inc

ISPC
Add to Watchlist
1.880USD
+0.050+2.73%
Close 07-31 16:00ETQuotes delayed by 15 min
34.85KMarket Cap
LossP/E TTM

More Details of iSpecimen Inc Company

iSpecimen Inc. is a technology-driven company. The Company addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.

iSpecimen Inc Info

Ticker SymbolISPC
Company nameiSpecimen Inc
IPO dateJun 17, 2021
CEOField (Katharyn)
Number of employees24
Security typeOrdinary Share
Fiscal year-endJun 17
Address8 Cabot Road
CityWOBURN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08101
Phone17813016700
Websitehttps://www.ispecimen.com/
Ticker SymbolISPC
IPO dateJun 17, 2021
CEOField (Katharyn)

Company Executives of iSpecimen Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Avtar Dhaliwal
Mr. Avtar Dhaliwal
Independent Director
Independent Director
--
--
Ms. Katharyn (Katie) Field
Ms. Katharyn (Katie) Field
President, Chief Executive Officer, Treasurer, Secretary
President, Chief Executive Officer, Treasurer, Secretary
--
--
Ms. Yuying Liang, CPA
Ms. Yuying Liang, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Siyun Yang
Ms. Siyun Yang
Independent Director
Independent Director
--
--
Mr. Anthony Lau
Mr. Anthony Lau
Independent Director
Independent Director
--
--
Mr. Arphing (Tommy) Lee
Mr. Arphing (Tommy) Lee
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Avtar Dhaliwal
Mr. Avtar Dhaliwal
Independent Director
Independent Director
--
--
Ms. Katharyn (Katie) Field
Ms. Katharyn (Katie) Field
President, Chief Executive Officer, Treasurer, Secretary
President, Chief Executive Officer, Treasurer, Secretary
--
--
Ms. Yuying Liang, CPA
Ms. Yuying Liang, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Siyun Yang
Ms. Siyun Yang
Independent Director
Independent Director
--
--
Mr. Anthony Lau
Mr. Anthony Lau
Independent Director
Independent Director
--
--
Mr. Arphing (Tommy) Lee
Mr. Arphing (Tommy) Lee
Independent Director
Independent Director
--
--

FAQs

Who are the top five shareholders of iSpecimen Inc?

The top five shareholders of iSpecimen Inc are: Mr. Avtar Dhaliwal

How many institutions hold shares of iSpecimen Inc (ISPC)?

As of 2026Q1, 31 institutions hold shares of iSpecimen Inc, with a combined market value of approximately 5.11K, accounting for 0.39% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -79730.00.

What is the biggest source of revenue for iSpecimen Inc?

In 2026Q1, the Specimens – contracts with customers business generated the highest revenue for iSpecimen Inc, amounting to 95.82K and accounting for 89.89% of total revenue.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.